Health Condition 1: F909- Attention-deficit hyperactivity disorder, unspecified type
Conditions
Interventions
None listed
Sponsors
Dr Dnyaneshwar G Kurle
Eligibility
Inclusion criteria
Inclusion criteria: A. Criteria for assessing prescription pattern, adverse drug reaction, awareness, cost: 1. Patient with the age less than 16 years diagnosed with ADHD according DSM 5 of either sex will be included. 2. Patients receiving drug treatment for ADHD. 3. Patients & legal authorized representative willing to give informed consent & participate in the study. Inclusion criteria for assessing effectiveness of drugs used in ADHD: 1. Patient with the age from 6 to 16 years diagnosed with ADHD according DSM 5 of either sex will be included. 2. Patients receiving single drug either methylphenidate or atomoxetine will be included. 3. Patients & legal authorized representative willing to give informed consent & participate in the study. 4. Patient who are able to understand and do the computerised psychometric test
Exclusion criteria
Exclusion criteria: Criteria for assessing prescription pattern, adverse drug reaction, awareness, cost: Patient not satisfying inclusion criteria will be excluded from the study. Criteria for assessing effectiveness of drugs used in ADHD: 1. Patients with other known neurological or gross organic diseases or other psychiatric disorder or substance abuse. 2. Patient taking psychoactive medications other than the study drugs. 3. Patients with motor tics. 4. Patient who are not able to understand or follow the instructions for doing the tes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prescription pattern will asses by Prescription daily dose (PDD) / defined daily dose(DDD) with complete or incomplete prescription.Timepoint: Asses on first visit of participant. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)To compare the effectiveness of methylphenidate & atomoxetine Connersâ?? Parent Rating Scales-Revised (CPR-R), clinical global impression scale (CGIS) & computerized psychometric tests will be used. 2) Adverse drug reaction -Causality will be judged using WHO UMC (Uppsala Monitoring Centre) scale. 3)Awareness about treatment- will be assessed by questionnaire validated by six experts and consisting of 11 questions. 4) Cost- Average total cost/ prescription Average hospital pharmacy cost/ prescriptionTimepoint: For comparing effectiveness new patient will be recruited hence baseline reading and then follow up after 6 to 8 week will be taken and second reading will be taken during this time. Adverse drung reaction , awareness and cost will be asses during first visit only. there wont be any follow up period for this outcome. | — |
Countries
India
Contacts
Public ContactDr Ajinkya Parhe
Principal Investigator
Outcome results
None listed